Oral Janus Kinase Inhibitors in Pediatric Vitiligo: A Real-World Retrospective Cohort Study
Description
This repository contains the supplementary material accompanying the above article. The material provides expanded methodological detail and additional descriptive analyses that support, but are not essential to, the findings reported in the main text. All data are derived from a single-center retrospective cohort of 112 pediatric patients (≤18 years) with active vitiligo treated with oral Janus kinase (JAK) inhibitors, with or without concomitant phototherapy, at the Dermatology Hospital of Shandong First Medical University. The data cut-off was April 2026. No individually identifiable patient information is included. The file contains the following items: Supplemental Methods. Expanded description of the study design, patient selection, treatment protocols (oral JAK inhibitor dosing, concomitant topical therapy, and phototherapy regimens), prior treatment history, baseline anatomical distribution of lesions, outcome assessment, and the criteria used to define disease activity and stability (graded by the Vitiligo Disease Activity [VIDA] score and assessed clinically as the appearance of new lesions or expansion of existing lesions relative to the preceding visit). Supplemental Table 1. Baseline demographic and clinical characteristics of the full cohort (N = 112), including sex, age, disease duration, vitiligo subtype, baseline VIDA score, oral JAK inhibitor prescribed, and concomitant phototherapy modality. Categorical variables are presented as frequencies and percentages. Supplemental Table 2. Efficacy outcomes (median trunk-and-extremities VASI [TE-VASI] and facial VASI [F-VASI] percentage improvements, with corresponding absolute changes and numbers of assessable patients) stratified by JAK inhibitor agent, vitiligo subtype, and phototherapy modality. Subgroup analyses are descriptive; no formal statistical comparisons were performed. Supplemental Table 3. Complete adverse-event profile for the full cohort, reported as the number of affected patients, including rows for serious adverse events, major adverse cardiovascular events (MACE), and malignancy (all recorded as zero events). A footnote indicates that a small number of patients each experienced more than one event. Supplemental Figure 1. Median TE-VASI and F-VASI improvement by JAK inhibitor (upadacitinib, tofacitinib, abrocitinib). Supplemental Figure 2. Median TE-VASI and F-VASI improvement by vitiligo subtype (nonsegmental vs segmental). Supplemental Figure 3. Median TE-VASI and F-VASI improvement by JAK inhibitor and treatment-duration interval (upadacitinib and tofacitinib; abrocitinib not stratified owing to small sample size). Supplemental Figures 4–6. Representative clinical photographs of treated patients, illustrating repigmentation over the course of treatment. Written informed consent for publication of these images was obtained.